A COVID-19 vaccine produced in a partnership between Sanofi and GlaxoSmithKline showed strong results in a new trial, the companies announced on Monday. Interim results from a phase two trial showed development of antibodies against the CCP (Chinese Communist Party) virus in 95 to 100 percent of volunteers, who ranged in age from 18 to 95. “With these favourable results, we are set to progress to a global Phase 3 efficacy study. We look forward to generating additional data and working with our partners around the world to make our vaccine available as quickly as possible,” Thomas Triomphe, executive vice president and head of Sanofi Pasteur, said in a statement. “These positive data show the potential of this protein-based adjuvanted vaccine candidate in the broader context of the pandemic, including the need to address variants and to provide for booster doses,” Roger Connor, president of GSK Vaccines, added. The trial involved 722 volunteers …